Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis

17. februar 2017 opdateret af: Paul F. White, Phoenix Thera-lase Systems, LLC

Adjunct Use of the Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid-containing Medication on a PRN Basis

Hypothesis: Use of high level vs low level cold laser treatments will reduce chronic pain and the need for PRN opioid-containing analgesic medications.

Secondary Hypothesis: High level (vs low level) laser treatments will increase the patients level of physical activity and quality of sleep.

Studieoversigt

Detaljeret beskrivelse

Previous studies with low level laser therapy have reported beneficial effects on the level of pain in patients with a variety of chronic pain conditions.

We designed this controlled, double blind, randomized study to determine in the active laser group would have a reduction in the need for 'PRN pain medication'.

Screening Testing

  1. Urine-toxicology screen.
  2. Assessment of level of activity and range of motion and functional capacity evaluation for upper and/ or lower extremity.
  3. Current drug history and use of analgesic medications including both opioid and or non-opioid analgesic medications.
  4. Drug history and current medications along with non-traditional alternative treatments such as (e.g. acupuncture, massage, herbal treatments, etc.)

Protocol Outline After obtaining written informed consent, patients will be asked to complete all the pre-screening and "entry" questionnaires (e.g., SF-36).

11- point Verbal Rating Scale (VRS) for pain at rest and with physical activity (0= none to 10= severe), level of physical activity (0=inactive to 10= fully active), and quality of sleep (0=poor to 10=excellent).

Current analgesic [pain] medications both daily and PRN medications. Randomized into active (Phoenix Thera-Lase [ PTL]) or "Low level" PTL group using a computer generated random numbers table.

Treatment Sessions After obtaining written informed consent for participating in the study and signing the standard HIPPA forms, the patient will be asked to describe the location of their current pain symptoms.

Pre-treatment baseline assessments VRS for pain at rest and with physical activity (e.g. walking, climbing stairs) Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain).

Current opioid and non-opioid analgesic medication usage Clinical opioid withdrawal scale (COWS) at baseline (the COWS will be repeated at the end of the 1st, 2nd, and 3rd week of treatments).

Treatment sessions - Active or low level therapy for 20 - 40 min on Monday, Wednesday, and Friday for 3 weeks.

Post- treatment sessions VRS for pain at rest and with ambulation immediately after each treatment

After the end of 3-week treatment period Repeat pre-screening questionnaires. Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain).

Long-term Follow Up 30-days after the last treatment session, a standardized follow-up questionnaire will be administered.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

75

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Ofelia Loani Elvir Lazo, MD
  • Telefonnummer: 310-721-0590
  • E-mail: loanidoc@yahoo.com

Studiesteder

    • Texas
      • Dallas, Texas, Forenede Stater, 75231
        • Rekruttering
        • Phoenix Thera-Lase Systems
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

25 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female patients
  • 25-65 years of age
  • taking oral opiate-containing analgesic medication on a PRN
  • patient with chronic pain related to an accident, injury or major surgery occurring within the past three years
  • Patients with a potentially treatable pain condition
  • Patient wiling to complete a daily diary for recording their pain score, activity level, quality of sleep and all pain-related medications for the three-week study period

Exclusion Criteria:

  • Use of any opioid-containing pain medications for more than three years
  • History of alcohol or drug abuse, or drug-seeking behavior
  • Previous treatment for drug abuse in detox center or hospital
  • Current psychiatric condition which require centrally- active medications
  • Current excessive use of alcohol
  • Any unstable medical conditions (e.g. coronary artery disease, hepato-renal or pulmonary disease)
  • Patients not capable of consenting for themselves
  • Pregnant women
  • Women of child bearing potential not using acceptable birth control methods.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Low level 1 Watt

The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate "blinding" of both the operator and the patient.

Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.

Each treatment session will last for 20-40 minutes.

The Phoenix Thera-Lase System will be on 1 watt
Andre navne:
  • 1 watt
Eksperimentel: Phoenix Thera-Lase System 42

The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate "blinding" of both the operator and the patient.

Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.

Each treatment session will last for 20-40 minutes.

The Phoenix Thera-Lase System will be on 42 watts
Andre navne:
  • 42 Watts
Eksperimentel: Phoenix Thera-Lase System 74

The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate "blinding" of both the operator and the patient.

Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.

Each treatment session will last for 20-40 minutes.

The Phoenix Thera-Lase System will be on 74 watts
Andre navne:
  • 74 Watts

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Reduce chronic pain
Tidsramme: 1 month
1 month
reduce of opioid analgesic dosage.
Tidsramme: one month
one month

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Level of physical activity
Tidsramme: 1 month
It will be assessed with a questionnaire
1 month
Quality of sleep
Tidsramme: one month
It will be assessed with a questionnaire
one month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Paul F White, PhD, MD, Phoenix Thera-Lase Systems

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. november 2016

Primær færdiggørelse (Forventet)

1. december 2017

Studieafslutning (Forventet)

1. december 2017

Datoer for studieregistrering

Først indsendt

10. november 2016

Først indsendt, der opfyldte QC-kriterier

10. november 2016

Først opslået (Skøn)

15. november 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. februar 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. februar 2017

Sidst verificeret

1. februar 2017

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 20162211

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Smerte

Kliniske forsøg med Low level 1 Watt

3
Abonner